乳腺癌超声征象与分子生物学指标相关性的研究进展  

The Research Progress of Correlation between Ultrasound Findings and Molecular Biological Indicators of Malignant Breast Lesions

作　　者：林韵[1] 王小燕[1] 

机构地区：[1]广西壮族自治区人民医院超声科,南宁530021

出　　处：《医学综述》2014年第5期800-803,共4页Medical Recapitulate

基　　金：广西科学研究与技术开发计划项目(桂科攻0592007-2C)

摘　　要：新生血管生成是乳腺癌生长和转移的必要条件,乳腺癌超声造影能准确无创并可重复地评估乳腺癌新生血管。免疫组织化学相关分子生物学基因,如雌激素受体(ER)、孕激素受体(PR)、增殖细胞核抗原(Ki-67)、人表皮生长因子受体2(HER2)表达与乳腺癌的组织学类型、淋巴结转移及预后有关。部分研究表明,肿块毛刺征与ER、PR呈正相关;HER2阳性患者出现不均匀增强或灌注缺损的概率较大。探索乳腺癌超声表现与ER、PR、Ki-67、HER2的相关性,对乳腺癌的诊断、治疗方案的选择及预后都有指导作用。Angiogenesis is a necessary condition for growth and metastasis of breast cancer,breast ultrasound contrast can realize accurate and reproducible assessment of noninvasive breast cancer neovascularization. The bio- makers such as ER, PR, Ki-67, and HER2 have been confirmed to be correlated with histological type, lymph node metastases, and prognosis of breast cancer. Some studies show that mass burr is positively related with ER and PR ; the probability of non-uniform perfusion or perfusion defect increases in breast cancer with HER2 positive expres- sion. The further investigations into the association of ultrasound findings with ER, PR, Ki-67, HER2 may help to guide the diagnosis, treatment options and prognosis of breast cancer.

关 键 词：乳腺癌 超声征象 分子生物学指标 病理 

分 类 号：R737.9[医药卫生—肿瘤] R445.1[医药卫生—临床医学]